Janssen Scientific Affairs (United States)

Recent papers from Janssen Scientific Affairs (United States)

1. Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity with Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results from ApexThe Journal of Rheumatology · 2026
2. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and AlbuminuriaJournal of the American College of Cardiology · 2022
3. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillationEuropean Heart Journal · 2015
4. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 DiabetesJournal of the American College of Cardiology · 2017
5. Patient perspectives on the challenges, obstacles, and opportunities in discussing and managing anhedonia in major depressive disorder (MDD): a focus group studyAnnals of General Psychiatry · 2026
6. Ciltacabtagene Autoleucel out-of-Specification Manufacturing Outcomes Improve with Earlier Lines of TherapyTransplantation and Cellular Therapy · 2026
7. Outpatient Versus Inpatient Administration of Ciltacabtagene Autoleucel in Multiple Myeloma: A Systematic Review of Clinical, Economic, and Humanistic OutcomesCancers · 2026
8. FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-TClinical Lymphoma Myeloma & Leukemia · 2026
9. Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamineBMC Psychiatry · 2025
10. Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United StatesJournal of Medical Economics · 2025
11. Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans AffairsJournal of Comparative Effectiveness Research · 2025
12. Net present value cost analysis for treating retinitis pigmentosa.2025
13. Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals: An analysis using the Premier Healthcare DatabaseJournal of Managed Care & Specialty Pharmacy · 2025
14. The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South AfricansSouthern African Journal of HIV Medicine · 2025
15. A systematic literature review of the association between global brain atrophy and the Expanded Disability Status Scale score in people with multiple sclerosisTherapeutic Advances in Neurological Disorders · 2025
16. Association between anhedonia severity and clinical, humanistic, and economic outcomes among US adults with major depressive disorderThe International Journal of Neuropsychopharmacology · 2025
17. Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration routeTherapeutic Advances in Hematology · 2025
18. Evaluation of Blood Pressure Control, Medication Adherence, and Therapeutic Inertia in US Patients With Hypertension Prescribed Multiple AntihypertensivesJournal of the American Heart Association · 2025
19. Elevating the Patient Voice: Understanding Treatment Preferences in Patients with Advanced Prostate CancerAdvances in Therapy · 2025
20. Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLLBlood Advances · 2025